PTCHF (PTCHF) Stock Price & Analysis
PTCHF (PTCHF) fell 3.33% to USD 1.8 as of June 10, 2026 at 02:36 UTC, according to Nexqual real-time market data.
PTCHF last closed at USD 1.86; the session ranged USD 1.8–1.8 on volume of 4,860 shares. Market capitalization is $438.15M, with a 52-week range of USD 1.55–1.92 (PNK). Source: Nexqual, June 10, 2026 at 02:36 UTC.
Key Statistics (as of June 10, 2026 at 02:36 UTC)
| Price | USD 1.8 |
|---|---|
| Change | ▼ 3.33% (down) |
| Previous Close | USD 1.86 |
| Open | USD 1.8 |
| Day Range | USD 1.8 – 1.8 |
| 52-Week Range | USD 1.55 – 1.92 |
| Volume | 4,860 shares |
| Market Cap | $438.15M |
| Exchange | PNK |
Technical Analysis (PTCHF)
Nexqual's technical model rates PTCHF "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 02:36 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.36 (neutral) |
| vs SMA50 | Above (USD 1.72) |
| MACD | 0.04 (positive) |
Analyst Ratings (PTCHF)
Wall Street analysts rate PTCHF "None", per Nexqual as of June 10, 2026 at 02:36 UTC.
| Consensus Rating | None |
|---|
Earnings (PTCHF)
| Next Earnings Date | 2026-04-29 |
|---|
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financials & Fundamentals (PTCHF)
| Total Revenue | $4.66M |
|---|---|
| Revenue Growth (YoY) | -38.20% |
| Gross Margin | +0.00% |
| Operating Margin | -1797.79% |
| Profit Margin | +0.00% |
| ROE | -30.85% |
| Debt / Equity | 66.49 |
| Current Ratio | 6.59 |
| Total Cash | $288.72M |
| Total Debt | $203.26M |
| Free Cash Flow | $-89.99M |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financial Health Score (PTCHF)
Nexqual rates PTCHF's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:36 UTC.
| Growth | Weak — Revenue -4% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $289M cash vs $203M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$90M, burning cash |
| Efficiency | Critical — ROE -31%, ROA -10.8% |
Ownership (PTCHF)
| Insider Ownership | +13.05% |
|---|---|
| Institutional Ownership | +60.15% |
| Shares Outstanding | 243.42M |
| Float | 157.41M |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Leadership (PTCHF)
PTCHF is led by Robert Lyne J.D., L.L.B. (age 42), CEO & Director, per Nexqual as of June 10, 2026 at 02:36 UTC.
| CEO & Director | Robert Lyne J.D., L.L.B. (age 42) |
|---|---|
| Co-Founder & Non-Executive Director | Robert S. Langer Jr., Ph.D., ScD (age 76) |
| Co-Founder & President | Eric Elenko (age 52) |
| Chief Financial Officer | Lauren A. White (age 46) |
| COO, General Counsel & Company Secretary | Charles Sherwood III |
Major Backers & Investors (PTCHF)
Notable institutional backers of PTCHF include DFA INVESTMENT TRUST CO-The United Kingdom Small Company Series, according to Nexqual as of June 10, 2026 at 02:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT TRUST CO-The United Kingdom Small Company Series | 0.5% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PRTCY | PureTech Health PLC | USD 16.43 | ▼ 2.56% |
| PHGUF | Pharming Group NV | USD 1.18 | ▲ 0% |
| TLPPF | Telix Pharmaceutical Ltd. | USD 9.5 | ▲ 0% |
| OXBDF | Oxford Biomedica PLC | USD 8.44 | ▲ 6.63% |
| CALZF | Polynovo Ltd. | USD 0.6 | ▼ 24.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:36 UTC. This page is informational and not investment advice.